Cindy Ann Dickerson

US Patent:

8003102, Aug 23, 2011

Filed:

Dec 17, 2010

Appl. No.:

12/971057

Inventors:

Cindy Takeuchi Dickerson - San Diego CA, US
David Matthew Marquis - Encinitas CA, US
Victor H Obungu - Fishers IN, US
Peter Edward Vaillancourt - Del Mar CA, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 39/395
A61K 39/00
C07K 16/00
C12P 21/08

US Classification:

4241411, 4241391, 4241431, 5303871, 5303873, 5303879, 5303881, 53038822

Abstract:

The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.

US Patent:

7892546, Feb 22, 2011

Filed:

May 7, 2009

Appl. No.:

12/436925

Inventors:

Cindy Takeuchi Dickerson - San Diego CA, US
David Matthew Marquis - Encinitas CA, US
Victor H. Obungu - Fishers IN, US
Peter Edward Vaillancourt - Del Mar CA, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 39/00
A61K 39/395
C07K 16/00
C12P 21/08

US Classification:

4241331, 4241391, 4241411, 4241431, 4241441, 5303871, 5303873, 5303879, 5303881, 53038815, 53038822

Abstract:

The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.

US Patent:

20210238684, Aug 5, 2021

Filed:

Apr 26, 2019

Appl. No.:

17/051731

Inventors:

- Los Angeles CA, US
- San Diego CA, US
Stephan TARGAN - Los Angeles CA, US
Alka POTDAR - Cumming CA, US
Jeffry D. WATKINS - Encinitas CA, US
Cindy T. DICKERSON - Encinitas CA, US

International Classification:

C12Q 1/6883
C07K 16/28
A61P 1/00
A61P 37/06

Abstract:

Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohns disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.

US Patent:

20210122828, Apr 29, 2021

Filed:

Dec 2, 2020

Appl. No.:

17/110004

Inventors:

- San Diego CA, US
Cindy T. Dickerson - Encinitas CA, US
Rafael Rojas - San Marcos CA, US
Matthew Reissman - San Diego CA, US
Patricia McNeeley - San Diego CA, US

International Classification:

C07K 16/28
A61P 1/04

Abstract:

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

US Patent:

20210070871, Mar 11, 2021

Filed:

Apr 24, 2019

Appl. No.:

17/050064

Inventors:

- San Diego CA, US
Cindy T. DICKERSON - Encinitas CA, US
J. Monty WATKINS - Encinitas CA, US
Patricia MCNEELEY - Encinitas CA, US

International Classification:

C07K 16/28
A61P 1/00
A61K 9/00

Abstract:

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohns Disease (CD) and ulcerative colitis (UC).

US Patent:

20200255510, Aug 13, 2020

Filed:

Apr 30, 2020

Appl. No.:

16/863971

Inventors:

- San Diego CA, US
Cindy T. Dickerson - Encinitas CA, US
J. Monty Watkins - Encinitas CA, US

International Classification:

C07K 16/24
A61P 1/04
C07K 16/28

Abstract:

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

US Patent:

20200157203, May 21, 2020

Filed:

Nov 25, 2019

Appl. No.:

16/694814

Inventors:

- San Diego CA, US
Cindy T. Dickerson - Encinitas CA, US
J. Monty Watkins - Encinitas CA, US

International Classification:

C07K 16/24
A61P 1/04

Abstract:

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

US Patent:

20160060328, Mar 3, 2016

Filed:

Oct 29, 2015

Appl. No.:

14/803637

Inventors:

- San Diego CA, US
Cindy Takeuchi DICKERSON - Encinitas CA, US
Barbara VISENTIN - Del Mar CA, US
Roger A. SABBADINI - Bend OR, US

International Classification:

C07K 16/18
A61K 45/06
A61K 39/395

Abstract:

Methods are provided for using antibodies and antibody fragments that bind one or more cysteinyl leukotrienes (cysLTs) for treatment of diseases, including inflammatory, respiratory and gastrointestinal diseases and conditions associated with aberrant levels of one or more cysLTs. Anti-cysLT antibodies and antigen-binding antibody fragments, and compositions containing such antibodies and antibody fragments, are also provided.